These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Statin therapy with ezetimibe or niacin in high-risk patients. Kastelein JJ; Bots ML N Engl J Med; 2009 Nov; 361(22):2180-3. PubMed ID: 19915218 [No Abstract] [Full Text] [Related]
3. Niacin compared with ezetimibe. Duivenvoorden R; Vergeer M; Kastelein JJ N Engl J Med; 2010 Mar; 362(11):1046-7; author reply 1048. PubMed ID: 20301795 [No Abstract] [Full Text] [Related]
4. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related]
5. Use of combination therapy for dyslipidemia: a lipid clinic approach. Brown AS Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy for dyslipidemia: safety and regulatory considerations. Davidson MH Am J Cardiol; 2002 Nov; 90(10B):50K-60K. PubMed ID: 12467940 [TBL] [Abstract][Full Text] [Related]
7. Therapy: raising HDL cholesterol levels: a flight of Icarus? Rossi GP; Rizzoni D Nat Rev Endocrinol; 2010 May; 6(5):245-6. PubMed ID: 20414314 [No Abstract] [Full Text] [Related]
8. The HALTS trial--halting atherosclerosis or halted too early? Blumenthal RS; Michos ED N Engl J Med; 2009 Nov; 361(22):2178-80. PubMed ID: 19915216 [No Abstract] [Full Text] [Related]
13. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154 [TBL] [Abstract][Full Text] [Related]
14. Achieving cholesterol goals. Current and future drug therapies. Jones PH Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635 [TBL] [Abstract][Full Text] [Related]
15. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Geiss HC; Otto C; Parhofer KG Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435 [TBL] [Abstract][Full Text] [Related]
16. Trial clouds use of niacin with a statin. Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606 [No Abstract] [Full Text] [Related]
17. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118 [TBL] [Abstract][Full Text] [Related]
18. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients. Savvidaki E; Koukoulaki M; Benou A; Roumeliotou M; Fourtounas C; Kalliakmani P; Papachristou E; Vlachojannis JG; Goumenos D Clin Nephrol; 2011 Feb; 75(2):107-12. PubMed ID: 21255539 [TBL] [Abstract][Full Text] [Related]
19. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
20. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. Phillips W; Schaefer S Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]